Skip to main content

Aligos Therapeutics, Inc.

corporate_fare Company Profile

Aligos Therapeutics, Inc.

ALGS·NASDAQ·Life Sciences·CIK 0001799448

Aligos Therapeutics, Inc. is a clinical-stage biotechnology company developing new treatments for liver diseases and viral infections. The company focuses on chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections (such as SARS‑CoV‑2, SARS‑CoV, MERS‑CoV, and related infections). Aligos's drug candidate pipeline includes pevifoscorvir sodium (previously ALG-000184) for chronic HBV infection, ALG‑055009 for MASH and obesity, and ALG‑097558 for coronavirus infections, along with preclinical programs. Pevifoscorvir sodium is a Capsid Assembly Modulator (CAM‑E) for chronic HBV infection. Preclinical testing showed enhanced pharmacologic properties compared to competitor CAM‑E drugs and greater HBV DNA suppression than standard nucleos(t)ide analogs (NAs). A multi‑part Phase 1 clinical trial, spanning up to 96 weeks, demonstrated multi-log 10 reductions in viral antigens. ALG‑055009 is a thyroid hormone receptor beta (THR‑β) agonist for MASH and obesity. Data to date suggest enhanced pharmacologic properties compared to competitor THR‑β agonists. Phase 2a topline data showed that ALG‑055009 dose groups met the primary endpoint with statistically significant reductions in liver fat at Week 12, measured by Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF), in subjects with presumed MASH. Recent nonclinical data indicate synergistic fat mass loss when combined with incretin receptor agonists in diet-induced obese (DIO) mice. ALG‑097558 is a small molecule coronavirus 3CL protease inhibitor (PI). It is at least 3‑fold more potent in cell‑based assays of coronavirus infection than other approved CoV PIs. Based on Phase 1 clinical studies, the company believes it can be dosed twice daily without requiring ritonavir co-dosing.

Aligos Therapeutics, Inc. (NASDAQ:ALGS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 21 items for ALGS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Aligos Therapeutics Reports $1.91 Per Share Loss for Fourth Quarter

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$2.19M
Net Income
-$24.19M
Diluted EPS
-$2.45
Op. Cash Flow
-$82.5M
Operating Income
-$87.98M
Cash & Equivalents
$18.3M
Debt / Equity
0.00×
Net Margin
-11.07×
Shares Outstanding
6.18M sh
Source: 10-K · filed 2026-03-05 · accession 0001193125-26-092614
$1.17 -4.09% today
52-week range · as of 2026-11-06 $1.17 – $13.69
Market cap
$8.6M
Volume
106.8K (1.6× avg)
3-mo avg 68.8K
Live data · 2026-11-22 12:44 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed ALGS - Filings & News (Page 2)

ALGS
Mar 05, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $7.20
Real-time Price: $1.17 info
Change: -$6.03 (-84%) info
Market Cap: $8.599M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets